The perils of combination antithrombotic therapy and potential resolutions

Circulation

Volumn 123, Issue 3, 2011, Pages 232-235

  Fisher, Marc ^c   Loscalzo, Joseph ^a,b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c University of Massachusetts   (United States)

Author keywords

antithrombotics; Editorials; prevention

Indexed keywords

ACENOCOUMAROL; ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; CLOPIDOGREL; DABIGATRAN; PLACEBO; RIVAROXABAN; WARFARIN; XIMELAGATRAN;

BLEEDING; BRAIN ISCHEMIA; CAROTID ARTERY STENTING; CORONARY ARTERY DISEASE; DRUG MEGADOSE; EMBOLISM; HEART ATRIUM FIBRILLATION; HEART INFARCTION; HEART VALVE PROSTHESIS; HUMAN; LOW DRUG DOSE; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; REVIEW; STROKE; THROMBOSIS;

ACUTE CORONARY SYNDROME; DRUG THERAPY, COMBINATION; FIBRINOLYTIC AGENTS; HUMANS; RISK FACTORS; STROKE; THROMBOSIS;

EID: 79251553499     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIR.0b013e31820841ce     Document Type: Review

References (34)

1. Hart RJ, Benavente O, McBride R, Pearce LA. Antithrombotic therapy to prevent stroke in patients with atrial fibrillation. Ann Intern Med. 1999; 131:492-501.
2. Clappers N, Brouwer MA, Verheugt FWA. Antiplatelet treatment for coronary artery disease. Heart. 2007;93:258-265.
3. Rubboli A, Halpern JL, Airaksinen KEJ, Buerke M, Eeckhout M, Freedman JB, Gershlick AH, Schlott A, Tse HF, Verheught FWA, Lip GYH. Antithrombotic therapy in patients treated with oral anticoagulation undergoing coronary artery stenting: an expert consensus document with focus on atrial fibrillation. Ann Med. 2008;40:428-436.
4. Hylek EM, Evans-Molina C, Shea C, Henault L, Regan S. Major hemorrhage and tolerability of warfarin in the first year of therapy among elderly patients with atrial fibrillation. Circulation. 2007;115:2689-2696.
5. Witt D, Sadler MA, Shanahan RL, Mazzoli G Tillman DJ. Effect of a centralized clinical pharmacy anticoagulation service on the outcomes of anticoagulation therapy. Chest. 2005;127:1515-1522.
6. Fang MC, Chang Y, Hylek EM, Rosand J, Greenberg SM, Gao AS, Singer DE. Advanced age, anticoagulation intensity, and risk for intra-cranial hemorrhage among patients taking warfarin for atrial fibrillation. Ann Intern Med. 2004;141:745-752.
7. Hart RG, Tonarelli SB, Pearce LA. Avoiding central nervous system bleeding during antithrombotic therapy: recent data and ideas. Stroke. 2005;36:1588-1593.
8. Shireman TI, Howard PA, Kresonik TF, Ellerback EF. Combined anticoagulant-antiplatelet use and major bleeding events in elderly atrial fibrillation patients. Stroke. 2004;35:2212-2267.
9. Flaker GC, Gruber M, Connolly SJ, Goldman S, Chaparro S, Vabanian A, Halinen MO, Horrow J, Halperin JJ, the SPORTIF Investigations. Risks and benefits of combining aspirin with anticoagulation therapy in patients with atrial fibrillation; an exploratory analysis of stroke prevention using an oral thrombin inhibitor in atrial fibrillation (SPORTIF) trials. Am Heart J. 2006;152:967-973.
10. Berwaerts J, Webster J. Analysis of risk factors involved in oral-anticoagulation-related intracerebral hemorrhage. Q J Med. 2000;93: 513-521.
11. Hansen ML, Sorensen R, Clausen MT, Fog-Petersen ML, Raunso J, Gadsboll N, Gislason GH, Folke F, Andersen SS, Schramm T, Abildstrom SZ, Poulsen HE, Kober L, Torp-Pedersen C. Risk of bleeding with single, dual or triple therapy with warfarin, aspirin and clopidogrel in patients with atrial fibrillation. Arch Intern Med. 2010;170:1433-1441.
12. Husted SE, Ziegler BK, Kher A. Long-term anticoagulant therapy in patients with coronary artery disease. Eur Heart J. 2006;27:913-919.
13. Breddin K, Loew D, Lechner K, Oberla K, Walter E. The German-Austrian Aspirin Trial: a comparison of acetylsalicylic acid, placebo and phenocoumon in secondary prevention of myocardial infarction. Circulation. 1980;62(suppl V):V-63-V-72.
14. EPSIM Research Group. A controlled comparison of aspirin and oral anticoagulants in prevention of death after myocardial infarction. N Engl J Med. 1982;307:701-708.
15. Julian DG, Chamberlain DA, Pocock SJ. A comparison of aspirin and anticoagulation following thrombolysis for myocardial infarction (the AFTER study): a multicenter unblinded randomized clinical trial. BMJ. 1996;313:1429-1431.
16. Hurlen M, Abdelnoor M, Smith P, Eriksson J, Arnesen H. Aspirin, warfarin or both after myocardial infarction. N Engl J Med. 2002;347:969-974.
17. Van Es RF, Jonker JJ, Verheught FW, Deckers JW, Grobbee DE. Aspirin and Coumadin after acute coronary syndromes (the ASPECT-2 Study): a randomized controlled trial. Lancet. 2002;360:109-113.
18. Mehta SR, Yusuf S, Peters RJG, Bertrand ME, Lewis BS, Natarajan MK, Malmberg K, Rupprecht HJ, Zhao F, Chrolavicius S, Copland I, Fox AA. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet. 2001;358:527-533.
19. Steinbuhl SR, Berger PB, Mann JT, Fry ETA, Delago A, Wilmer C, Topol EJ, for the CREDO Investigators. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. J Am Med Assoc. 2002;288:2411-2420.
20. Kushner FG, Hand M, Smith SC, King SB, Anderson JL, Antman EM, Bailey SR, Bates ER, Blankenship JC, Casey DE, Green LA, Hochmabn JS, Jacobs AK, Krumholz HM, Morrison DH, Ornato JP, Pearle DP, Peterson ED, Sloan MA, Whitlow PL, Williams DO. 2009 Focused Updates: ACC/AHA Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction (Updating the 2004 Guideline and 2007 Focused Update) and ACC/AHA/SCAI Guidelines on Percutaneous Coronary Intervention (Updating the 2005 Guideline and 2007 Focused Update): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2009;54:2205-2241.
21. Kimura T, Morimoto T, Nakagawa Y, Tamura T, Kadota K, Yasumoto H, Nishikawa H, Hiasa Y, Muramatsu T, Meguro T, Inoue N, Honda H, Hayashi Y, Miyazaki S, Oshima S, Honda T, Shiode N, Namura M, Sone T, Nobuyoshi M, Kita T, Mitsudo K, for the j-Cypher Registry Investigators. Antiplatelet therapy and stent thrombosis after sirolimus-eluting stent implantation. Circulation. 2009;119:987-995.
22. Park S-J, Park D-W, Kim Y-K, Kang S-J, Lee S-W, Lee CW, Han K-H, Park SW, Yun S-C, Lee S-G, Rha S-W, Seong I-W, Jeong M-H, Hur S-H, Lee N-H, Yoon J, Yang J-Y, Lee B-K, Choi Y-J, Chung W-S, Lim D-S, Cheong S-S, Kim K-S, Chae JK, Nah D-Y, Jeon D-S, Seung KB, Jang J-S, Park HS, Lee K. Duration of dual antiplatelet therapy after implantation of drug-eluting stents. N Engl J Med. 2010;362:1374-1382.
23. Lip GYH, Huber K, Anderotti F, Arnesen H, Airaksinen J, Cuisset T. Management of antithrombotic therapy in atrial fibrillation patients presenting with coronary syndrome or undergoing percutaneous coronary intervention/ stenting. Thromb Haemost. 2010;103:13-28.
24. Bhatt DL, Fox KA, Hacke W, Berger PE, Black HR, Boden WE, Cacoub P, Cohen EA, Creager MA, Easton JD, Flather RD, Hafner SM, Hamm CW, Hankey GJ, Johnson SC, Mak K-H, Mas J-L, Montalescot G, Pearson TA, Steg PG, Steinbuhl S, Weber MA, Brennan DM, Fabri-Ribaudo L, Booth J, Topol EJ, for the CHARISMA Investigators. Clo-pidogrel and aspirin versus aspirin alone for the prevention of athero-thrombotic events. N Eng J Med. 2006;354:1706-1717.
25. Diener HC, Bogousslavsky J, Brass LM, Cimminiello C, Csiba L, Kaste M, Leys D, Matais-Guiu J, Ruprecht H-J. Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial. Lancet. 2004;364:331-337.
26. Holmes DR, Kereiakes DJ, Kleiman NS, Moliterno DJ, Patti G, Grines CL. Combining antiplatelet and anticoagulant therapies. J Am Coll Cardiol. 2009;54:95-109.
27. Gao F, Zhou YJ, Wang ZJ, Shen H, Liu XL, Yan ZX, Yang SW, Jia DA, Yu M. Comparison of different antithrombotic regimens for patients with atrial fibrillation undergoing drug-eluting stent implantation. Circulation. 2010;74:701-708.
28. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, Pogue J, Reilly PA, Themeles BA, Varrone J, Wang S, Alings M, Xavier D, Zhu J, Diaz R, Lewis BS, Dariius H, Diener H-C, Joyner C, Wallentin L, and the RE-LY steering committee. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361:1139-1151.
29. Weber R, Diener H-C, Weimar C. Prevention of cardioembolic stroke in patients with atrial fibrillation. Exp Rev Cardiovasc Therapy. 2010;8: 1405-1416.
30. Patel MR, for The ROCKET investigators. Stroke prevention using the oral direct factor Xa inhibitor rivaroxaban compared with warfarin in patients with nonvalvular atrial fibrillation (ROCKET AF). Circulation. 2010;122:A21839. Abstract.
31. Wiviott SD, Trenk D, Frelinger AL. Prasurgel compared with high-loading and maintenance-dose clopidogrel in patients with percutaneous coronary intervention: the Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation-Thrombolysis in Myo-cardial Infarction 44 trial. Circulation. 2007;116:1038-1047.
32. Montalescot G, Wiviott SD, Braunwald E, Murphy SA, Gibson CM, McCabe CH, Antman EM; TRITON-TIMI 38 Investigators. Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomized controlled trial. Lancet. 2009;373:723-731.
33. Cannon CP, Harrington RA, James S, Ardissino D, Becker RC, Eman-uelsson H, Husted S, Katus H, Keltai M, Khurmi NS, Kontny F, Lewis BS, Steg PG, Storey RF, Wojdyla D, Wallentin L; PLATelet inhibition and patient Outcomes Investigators. Comparison of ticagrelor with clo-pidogrel in patients with a planned invasive strategy for acute coronary syndromes (PLATO): a randomized double-blind study. Lancet. 2010; 375:283-293.
34. Miyasaka Y, Barnes ME, Gersh BJ, Cha SS, Barley KR, Abhayaratna WP, Seward JB, Tsang TS. Secular trends in incidence of atrial fibrillation in Olmsted County, Minnesota, 1980-2000, and implications on the projections for future prevalence. Circulation. 2006;114:119-125.